Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274755 · ClinicalTrials.gov registry record · Phase 2
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT00274755 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by University of California, San Francisco. The registered enrollment target is 250 participants, above the 178-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (40% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00274755, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI), (done before, during, and after treatment) may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial is studying how well MRI and MRSI evaluate patients who are undergoing treatment for gliomas.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- PROCEDURE magnetic resonance spectroscopic imaging
- DRUG chemotherapy
- PROCEDURE magnetic resonance imaging
Study Locations (1)
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2003-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274755
The ClinicalTrials.gov registry entry for NCT00274755 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 178-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (40% higher). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 5 interventions - of which conventional surgery is the first listed.
NCT00274755 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00274755 about?
NCT00274755 is a clinical study titled "Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas". RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI), (done before, during, and after treatment) may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial is stu...
What is the current status of trial NCT00274755?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2003-11.
What conditions does trial NCT00274755 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00274755?
The interventions under investigation include: conventional surgery (PROCEDURE), radiation therapy (RADIATION), magnetic resonance spectroscopic imaging (PROCEDURE), chemotherapy (DRUG), magnetic resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00274755?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00274755 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Combination Chemotherapy for Patients With Brain Cancer
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
COMPLETED · Phase 2
-
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.